U.S. Govt Slashes Medicare Drug Prices by Up to 79%

The U.S. government announced a reduction of up to 79% in the prices of ten top-selling prescription drugs for Medicare beneficiaries. This move, enabled by the Inflation Reduction Act, aims to save $6 billion in the first year. Reactions to the price cuts were mixed, with government officials praising the negotiations while pharmaceutical companies voiced concerns.

The U.S. government announced on Thursday that it had successfully negotiated price reductions of up to 79% for ten top-selling prescription drugs covered by Medicare. This decision follows months of intense discussions with major drug manufacturers.

The price cuts, made possible by provisions in the Inflation Reduction Act, are expected to save $6 billion in the first year. Medicare covers approximately 66 million Americans, predominantly seniors, and the negotiated rates target the most costly medications in its portfolio.

President Joe Biden hailed the move, stating, 'We showed that major progress can be made for the American people when we work together to take on special interests.' However, pharmaceutical companies like AbbVie and Novo Nordisk expressed concerns about the long-term impact on innovation and patient benefits.